Prospective, Multicenter, Non-intervention Clinical Trial of Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer
Latest Information Update: 03 Dec 2019
Price :
$35 *
At a glance
- Drugs Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Dec 2017 New trial record